Mersana Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy MRSN

*Your capital is at risk

$29.08

+0 (+0%)

At Close: Apr 02, 2026

Mersana Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 534.81K MRSN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	534.81K shares
0% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Jan 06, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Dere Willard H Director	Director	1 000 Value: $107.8K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Dere Willard H Director	Director	800 Value: $347.6K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Dere Willard H Director	Director	2 460 Value: $22.3K
Jan 06, 2026 Sell	Common Stock U-Tender	Dere Willard H Director	Director	1 567 Value: $0
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	2 200 Value: $124.3K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	734 Value: $158.5K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	1 800 Value: $162.9K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	416 Value: $67.0K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	1 571 Value: $719.9K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Diaz Allene M. Director	Director	2 460 Value: $22.3K
Jan 06, 2026 Sell	Common Stock U-Tender	Diaz Allene M. Director	Director	578 Value: $0
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	2 088 Value: $214.0K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	2 200 Value: $124.3K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	257 Value: $14.6K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	380 Value: $12.0K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	146 Value: $12.5K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	734 Value: $158.5K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	138 Value: $14.7K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	1 800 Value: $162.9K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	416 Value: $67.0K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	1 002 Value: $373.2K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	101 Value: $53.3K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	368 Value: $210.7K
Jan 06, 2026 Sell	Stock Option (right to buy) D-Return	Hege Kristen Director	Director	450 Value: $60.3K
Jan 06, 2026 Sell	Restricted Stock Units D-Return	Mandelia Ashish Vp, Chief Accounting Officer	Officer	666 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MERSANA THERAPEUTICS, INC.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ...

Read Full Profile Here